Science & Tech

Durvalumab Plus FLOT Boosts Survival in Resectable Gastric and GEJ Cancer, MATTERHORN Shows

Phase 3 MATTERHORN shows AstraZeneca’s durvalumab added to perioperative FLOT improves overall and event‑free survival in resectable gastric/GEJ cancer.

$AZN, #oncology, #immunotherapy, #durvalumab, #gastric-cancer, #astrazeneca

Gene-edited pig kidney supported a human for 271 days and didn’t block later transplant, case report finds

A Lancet case report shows a gene-edited pig kidney kept a patient off dialysis for 271 days and didn’t impede a later human transplant.

#xenotransplantation, #kidneytransplant, #egenesis, #organtransplant

FDA Approves Zanvastro, First Therapy for Alexander Disease

FDA approves Zanvastro (zilganersen), the first approved therapy for Alexander disease, for patients from infancy through adulthood. Ionis received approval.

$IONS, #health, #fda, #alexanderdisease, #ionis

Sham-controlled trial finds pulmonary vein isolation no better than sham for atrial fibrillation quality of life at six months

A multicentre sham-controlled trial in Europe published in The Lancet found PVI didn’t improve AF-related quality of life versus sham at six months.

#atrialfibrillation, #catheterablation, #cardiology, #clinicaltrials

Phase 1 study: single dose of Kylo-11 sharply lowers Lp(a) for up to 48 weeks

A phase 1 trial in The Lancet found one dose of experimental siRNA Kylo-11 was well tolerated and cut Lp(a) by up to ~98% for months.

#lpa, #cardiology, #drugdevelopment, #sirna

FDA Approves Rasonque (daraxonrasib), First Targeted Therapy for Most Common Form of Metastatic Pancreatic Cancer

FDA cleared Rasonque for adults with previously treated metastatic pancreatic adenocarcinoma after a Phase 3 trial showed a significant overall survival benefit.

$RVMD, #health, #pancreaticcancer, #oncology, #drugapproval

FDA Clears Abbott’s Libre Duo 10 Day, First U.S. Wearable to Continuously Monitor Ketones and Glucose

FDA authorizes Abbott’s Libre Duo 10 Day, the first U.S. wearable to continuously monitor ketones and glucose for ages 2 and up.

#diabetes, #fda, #medicaldevices, #abbott

Study finds at least 24.5% of former NFL players who died 2016–2021 had CTE

Using deaths of 878 former NFL players (2016–2021), researchers estimate at least 24.5% had CTE, with a plausible prevalence range up to 97.7%.

#cte, #nfl, #braininjury, #neuroscience

NHS begins rolling out free at-home HPV self-test kits to nearly 4 million overdue for cervical screening

NHS England is inviting nearly 4 million people overdue for cervical screening to order free at-home HPV self-test kits to boost uptake and prevent cancer.

#nhs, #hpv, #cervicalscreening, #publichealth, #cancer

Statistics Canada links seven CHMS cycles to administrative health records for longitudinal research

Statistics Canada linked seven CHMS cycles (2007–2024) with administrative health records, letting approved researchers study biomarkers and later outcomes.

#statisticscanada, #healthsurvey, #researchdata, #chms

MHRA warns parents to stop using infant rectal 'gas' catheters and dispose of unused devices

MHRA warns parents and clinicians to stop using infant rectal catheters marketed for colic or gas and to dispose of unused devices, citing unknown risks.

#health, #mhra, #infants, #medicaldevices, #colic

UK regulator issues safety alert for some ResMed Astral ventilators after risk of sudden stoppage

UK regulator warns ResMed Astral 100/150 ventilators made before Oct 2024 can stop delivering therapy due to leaking supercapacitors; patients must not stop use.

#health, #safety, #medical-devices, #resmed

MHRA details pilot to cut Phase 1 clinical trial review to 14 days by end of 2026

MHRA outlines a staged pilot to reduce first-assessment times for eligible Phase 1 trials in healthy volunteers to 14 days by end-2026, with tight eligibility and limited slots.

#mhra, #clinicaltrials, #uk, #phase1

FDA approves Moderna’s first seasonal mRNA flu vaccine — full approval for 50–64, accelerated OK for 65+

FDA approved Moderna’s mRNA-1010 seasonal flu vaccine (mFLUSIVA), giving full approval for ages 50–64 and accelerated approval for 65+, pending a confirmatory study.

$MRNA, #moderna, #influenza, #fda, #vaccines

Once‑Weekly Oral HIV Pill Maintains Viral Suppression Through 48 Weeks in Phase 3 Trial

Phase 3 Lancet study: a once‑weekly islatravir‑lenacapavir single‑tablet regimen maintained HIV‑1 viral suppression through 48 weeks, matching daily therapy.

#hiv, #islatravir, #lenacapavir, #antiretroviral, #clinicaltrial